AngioDynamics Gears Up for First Quarter Earnings Release
AngioDynamics, Inc. (NASDAQ: ANGO) is set to unveil its earnings results for the first quarter soon, sparking significant anticipation among investors and analysts alike. The earnings announcement is expected before the market opens on an upcoming Thursday, marking a pivotal moment for the company.
Analyst Expectations for the Earnings Report
Experts have projected that the Latham-based company will report a quarterly loss of 12 cents per share. This is slightly worse than the loss of 11 cents per share reported during the same period last year. However, in terms of revenue, AngioDynamics is expected to report a total of $72.69 million for this quarter, reflecting a growth from $67.49 million compared to the prior year.
Recent Performance and Forward Guidance
In a preceding report published in July, AngioDynamics shared encouraging financial outcomes for their fourth quarter, surpassing expectations and even issuing a revenue guidance for the fiscal year that suggested potential growth beyond analyst forecasts.
Stock Movement and Market Reaction
In response to these developments, shares of AngioDynamics experienced a positive uptick, rising by 4% to close at $11.17 on one recent trading day. This upward trend highlights the market's confidence in the company’s ability to navigate its financial challenges and capitalize on growth opportunities.
Insights from Analysts on ANGO
Market analysts have been closely monitoring AngioDynamics and have shared their ratings and outlook. Recently, Yi Chen of HC Wainwright & Co. reaffirmed a Buy rating for ANGO with a price target of $16, reflecting a solid confidence level with an accuracy rate of 64%. In a similar vein, William Plovanic of Canaccord Genuity maintained a Buy rating and updated the price target from $15 to $17, showcasing a positive upward shift in expectation.
Analyst Ratings and Stock Buying Considerations
For those considering investing in AngioDynamics stock, the consistent Buy ratings from analysts may provide a reassuring sign. It’s crucial to weigh these recommendations alongside other market factors to make informed investment choices.
Looking Ahead: What’s Next for AngioDynamics?
As AngioDynamics approaches its earnings report, many market participants are keenly awaiting the results which could further solidify or challenge current analyst projections. The company's ability to meet or exceed these expectations will play a significant role in shaping its stock performance in the near future.
Frequently Asked Questions
What is the expected earnings loss for AngioDynamics?
Analysts expect AngioDynamics to report a quarterly loss of 12 cents per share for the upcoming earnings report.
What revenue growth does AngioDynamics project for the quarter?
The company expects to report quarterly revenue of $72.69 million, an increase from $67.49 million from the same quarter last year.
How have recent market trends affected AngioDynamics' stock?
Following positive fourth-quarter results and analyst endorsements, AngioDynamics' stock rose by 4% to close at $11.17 one trading day.
What ratings have analysts given AngioDynamics stock?
Analysts like Yi Chen and William Plovanic have reiterated Buy ratings, with price targets ranging from $16 to $17, indicating positive market sentiment.
Why is the upcoming earnings report significant?
The upcoming earnings report will be crucial for evaluating AngioDynamics' financial health and growth potential, which could influence investor decisions moving forward.
